Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen
The purpose of this study is to determine whether sequential application of low-dose short-term sunitinib and chemotherapy is effective in the treatment of non-small cell lung cancer after failure of conventional therapy. Safety of this regimen will also be evaluated.
Cancer|Lung Cancer
DRUG: Sunitinib, chemotherapy
progression-free survival, The primary objective of this study is to evaluate the median progression-free survival of this sequential regimen., up to 2 years
overall survival, To evaluate the median over-all survival of this regimen, up to 2 years|disease control rate, To evaluate the disease-control rate of this regimen., up to 6 months|Safety, To evaluate the safety of this regimen including the rate and grade of adverse effects., up to 2 years
The purpose of this study is to determine whether sequential application of low-dose short-term sunitinib and chemotherapy is effective in the treatment of non-small cell lung cancer after failure of conventional therapy. Safety of this regimen will also be evaluated.